Does clinical trial participation improve outcomes in patients with ovarian cancer?

por Khoja, L, Horsley, L, Heesters, A, Machin, J D, Mitchell, C, Clamp, AR, Jayson, GC, Hasan, J
Publicado 2016

Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers

por Zhou, C., O’Connor, J., Backen, A., Valle, J.W., Bridgewater, J., Dive, C., Jayson, G.C.
Publicado 2022

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial

por Ledermann, J.A., Embleton-Thirsk, A.C., Perren, T.J., Jayson, G.C., Rustin, G.J.S., Kaye, S.B., Hirte, H., Oza, A., Vaughan, M., Friedlander, M., González-Martín, A., Deane, E., Popoola, B., Farrelly, L., Swart, A.M., Kaplan, R.S., Parmar, M.K.B.
Publicado 2021